<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640016</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-354-0603</org_study_id>
    <secondary_id>2007-002090-31</secondary_id>
    <nct_id>NCT00640016</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge Antibody Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of CAT-354 on airway hyper-responsiveness (AHR) in uncontrolled
      asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, stratified, double-blind, placebo-controlled, multicenter,
      multinational study in subjects with uncontrolled asthma despite optimal treatment. Following
      confirmation of eligibility, subjects will be randomly assigned on Day 0, to 1 of 4 dose
      groups 1 mg/kg CAT-354, 5 mg/kg CAT-354, 10 mg/kg CAT or Placebo to match all doses of
      CAT-354. Doses of the assigned treatment will be administered on three occasions 28 days
      apart. Subjects will be assessed for efficacy, including airway hyper-responsiveness (AHR),
      safety, pharmacokinetic, pharmacodynamics and immunogenicity until Day 84 post-first dose.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated prematurely by the sponsor due to slow recruitment.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Doubling Concentration of Methacholine at Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 milligram/kilogram [mg/kg]) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Doubling Concentration of Methacholine at Day 56, 84 or Early Termination</measure>
    <time_frame>Baseline, Day 56, 84 or early termination (any time before Day 84)</time_frame>
    <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)</time_frame>
    <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)</time_frame>
    <description>The FVC was volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) as Percentage of Forced Vital Capacity (FVC)</measure>
    <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, Day 63, 84 or early termination (any time before Day 84)</time_frame>
    <description>Percentage of FEV1 was calculated as (FEV1/FVC)*100. It signified the percentage of the total amount of air exhaled from the lungs during the first second of forced exhalation. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ) Total Score</measure>
    <time_frame>Baseline, Day 28, 56, 84 or early termination (any time before Day 84)</time_frame>
    <description>The ACQ is questionnaire that comprises of 7-questions evaluating participant's asthma control. Six self-administered questions assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; using 7-point ordinal rating scale from 0 (good control) to 6 (poor control). Seventh question is completed by a health professional on forced expiratory volume in 1 second (FEV1) percentage (%) predicted; scale: 0 (greater than [&gt;] 95% predicted) to 6 (less than [&lt;] 50% predicted. Final score is the average score of the 7 questions, with a score range of 0 (well controlled) to 6 (extremely poor controlled). Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Day 0 to 84</time_frame>
    <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Diary Data</measure>
    <time_frame>Day 0, 4, 14, 28, 35, 56, 63 to Day and 84</time_frame>
    <description>Participants recorded asthma symptoms, use of reliever inhalers (beta-agonist use for symptom relief and as prophylaxis), and morning and evening peak expiratory flow (PEF) measurements in a diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Exacerbations</measure>
    <time_frame>Day 0 to Day 84</time_frame>
    <description>Exacerbation was defined as: Mild (determined from diary data) - 2 consecutive days satisfying the same or 1 of the following criteria: any night with awakening(s) due to asthma or morning PEF 20 % or more below baseline where baseline = average of the 10 days before randomization or as-needed medication use of 2 inhalations or more in 24 hours above baseline where baseline = average of the 10 days before randomization. Severe (determined by taking an exacerbation update and history): deterioration of asthma resulting in emergency treatment or hospitalization or need for oral steroids for 3 days or more (as judged by the Investigator).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Flow and Peak Flow Variability</measure>
    <time_frame>Day 0 to Day 84</time_frame>
    <description>Peak flow is a participant's maximum speed of expiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adult Asthma Quality of Life (QoL) Questionnaire Final Score</measure>
    <time_frame>Day 0, 28, 84 or early termination (any time before Day 84)</time_frame>
    <description>The AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants are asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. The 4 domain scores are the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) for CAT-354</measure>
    <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Concentration (Cmin) for CAT-354</measure>
    <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC [0 - t]) for CAT-354</measure>
    <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio for CAT-354 (RA)</measure>
    <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
    <description>Accumulation ratio (RA) is calculated for Cmax, Cmin and AUC as RA for Cmax = Cmax (56 - 84)/Cmax (0 - 28); Similarily, RA for Cmin = Cmin (56 - 84)/Cmin (0 - 28) and RA for AUC= AUC (56 - 84)/AUC (0 - 28) where Cmax (0 - 28) and Cmax (56 - 84) are the maximum observed serum concentration after first dose (Day 0 to Day 28) and after third dose (Day 56 to Day 84), respectively; Cmin (0 - 28) and Cmin (56 - 84) are the minimum observed serum concentration after first and third dose, respectively; AUC (0 - 28) and AUC (56 - 84) are the area under the serum concentration time curve over a dosage interval determined after first and third dose, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Day 0 to 84</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 84 that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-354 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-354 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAT-354 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAT-354 1 mg/kg</intervention_name>
    <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 1 mg/kg</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAT-354 5 mg/kg</intervention_name>
    <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 5 mg/kg</arm_group_label>
    <other_name>Tralokinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CAT-354 10 mg/kg</intervention_name>
    <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
    <arm_group_label>CAT-354 10 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent is obtained prior to any study related
             procedure taking place

          -  Women either infertile (example [e.g.], hysterectomized, sterile or post-menopausal
             with amenorrhea of least 1 year duration) or who are practicing an acceptable form of
             birth control

          -  Uncontrolled (refractory) asthma despite treatment with a minimum dose of 800
             microgram (mcg) beclomethasonedipropionate or equivalent inhaled corticosteroid per
             day plus 1 or more additional controller, that is, long-acting beta-agonist,
             leukotriene antagonist or theophylline. Oral corticosteroids (not parenteral) as
             additional treatment at any dose are acceptable

          -  A forced expiratory volume in 1 second (FEV1) acceptable for airway
             hyper-responsiveness (AHR) challenge tests (greater than 60 percent of predicted
             normal) on the challenge days

          -  A provocative concentration of methacholine causing a 20 percent fall in FEV1 (PC20)
             less than 4 milligram per milliliter (mg/mL)

          -  Aged 18-80 years

          -  A 12-lead electrocardiogram (ECG) with no-clinically significant abnormalities

          -  Clinical chemistry, hematology and urinalysis results within the laboratory reference
             ranges or deemed not clinically significant by the Investigator

          -  Body weight of less than 130 kilogram (kg)

          -  No other clinically significant abnormality on history and clinical examination

          -  Able to comply with the requirements of the protocol.

        Exclusion Criteria:

          -  Experienced a severe exacerbation within 28 days preceding Day -28/-14 to Day 0

          -  Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Day -28/-14
             to Day 0

          -  Subjects with a history of allergic rhinitis, seasonal allergy or esophagitis must be
             optimally controlled and remain on a stable treatment regimen during the study

          -  Participation in another study within 5 half-lives or 3 months of the start of this
             study, whichever is the longer

          -  Lower respiratory tract infection within 6 weeks of Day -28/-14 to Day 0

          -  Current smokers or ex-smokers with greater than 10 pack-years

          -  Blood donation (more than 550 mL) in the previous 2 months

          -  Excessive intake of alcohol (as judged by the Investigator) or evidence of drug or
             solvent abuse

          -  Subjects with a physician-diagnosis of any other significant lung disease, including a
             primary diagnosis of chronic obstructive pulmonary disease or bronchiectasis, or lung
             cancer, sarcoidosis, tuberculosis, pulmonary fibrosis and cystic fibrosis

          -  Concurrent medication from Day -28/-14 to Day 0 (Screening visit) and for the duration
             of the study with any of the prohibited medications

          -  Significant, uncontrolled disease including serious psychological disorders, chronic
             renal failure, uncontrolled hypertension

          -  systolic blood pressure greater than 200 millimeters of mercury (mmHg), or diastolic
             blood pressure greater than 100 mmHg, heart disease, psoriasis requiring treatment and
             subjects who have had a heart attack or stroke within the 3 months preceding Day
             -28/-14 to Day 0, or who have a known aneurysm

          -  Onset of uncontrolled seasonal allergy symptoms within 28 days preceding Day -28/-14
             to Day 0

          -  Subjects with a history of allergic rhinitis, seasonal allergy or esophagitis must be
             optimally controlled and remain on a stable treatment regimen during the study

          -  Any factor which, in the opinion of the Investigator, would jeopardize the evaluation
             or safety or be associated with poor adherence to the protocol (that is, inability to
             complete study diary, perform peak expiratory flow (PEF) measurements)

          -  The subject's primary care physician recommends the subject should not take part in
             the study

          -  Known hypersensitivity to CAT-354 or its components, to the challenge agents used in
             the study or to related drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Mayer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincents Hospital, Thoracic Medicine Unit</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Medicine Department, Mater Adult Hospital,</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandria Hospital, Dept of Respiratory Medicine</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Clinical Research Unit</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre, Dept Respiratory Medicine.</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep of Respiratory &amp; Sleep Medicine, Western Hospital</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory &amp; Sleep Medicine, Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Institute WA, Sir Charles Gardner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WA Lung Research, Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Lungenklinik Berlin - Kardiologie/Pneumologie - 1.OG, Haus 23</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Klinik m. S. Infektiologie und Pneumologie, Charite - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungen und Bronchialheikunde</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Lungen-und Bronchialheilkunde, Allergologie und Umweltmedizin</name>
      <address>
        <city>Bonn</city>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheinische Friedrich-Wilhelms-Universität, Medizinische Klinik und Poliklinik II, Innere Medizin</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistisches Facharztzentrum Stresemannallee</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg Fachbereich Pneumologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz, Klinische Forschung Pneumologie, III. med. Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Rostock, Medizinische Fakultät Klinik und Poliklinik für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus im Fläming gGmbH, Pneumologie</name>
      <address>
        <city>Treuenbrietzen</city>
        <zip>14929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Internistyczno-Alergologiczny</name>
      <address>
        <city>Bialystok</city>
        <zip>15-025</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPL Centrum Medyczne</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny Slaskiej Akademii Medycznej, Klinika Pneumologii</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Atopia</name>
      <address>
        <city>Kraków</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital ZOZ Lubin Oddzial Alergologiczny i Chorob Wewnetrznych</name>
      <address>
        <city>Lubin</city>
        <zip>59-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny, Poradnia Alergologiczna</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alergopneuma Przychodnia Alergologiczno-Pulmonologiczna Marek Michnar i wsp.</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Gruzlicy i Chorob Pluc</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny w Zgierzu</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny nr 1 Im. Norberta Barlickiego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <zip>91-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust, Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of South Manchester NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital</name>
      <address>
        <city>Newport</city>
        <zip>NP20 2UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage, Hertfordshire</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <results_first_submitted>June 3, 2016</results_first_submitted>
  <results_first_submitted_qc>December 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 31, 2017</results_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>CAT-354</keyword>
  <keyword>Tralokinumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P2">
          <title>CAT-354 1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P3">
          <title>CAT-354 5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="P4">
          <title>CAT-354 10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all participants who were enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B2">
          <title>CAT-354 1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B3">
          <title>CAT-354 5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B4">
          <title>CAT-354 10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.00" spread="11.136"/>
                    <measurement group_id="B2" value="34.00" spread="14.933"/>
                    <measurement group_id="B3" value="37.75" spread="9.878"/>
                    <measurement group_id="B4" value="40.75" spread="15.086"/>
                    <measurement group_id="B5" value="37.00" spread="11.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Doubling Concentration of Methacholine at Day 28</title>
        <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 milligram/kilogram [mg/kg]) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Doubling Concentration of Methacholine at Day 28</title>
          <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 milligram/kilogram [mg/kg]) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>log2 milligram/deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.604" spread="2.4080"/>
                    <measurement group_id="O2" value="-1.545" spread="0.8952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 28 (n=5, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.207" spread="1.0450"/>
                    <measurement group_id="O2" value="0.125" spread="2.3433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Doubling Concentration of Methacholine at Day 56, 84 or Early Termination</title>
        <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Baseline, Day 56, 84 or early termination (any time before Day 84)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure, and 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Doubling Concentration of Methacholine at Day 56, 84 or Early Termination</title>
          <description>Change in doubling concentrations of methacholine was calculated as Log2 PC20 (Visit x) - Log2 PC20 (Baseline), where x was the post-baseline assessment (Day 28) and PC20 was provocative concentration of methacholine causing 20 percent fall in forced expiratory volume in 1 second (FEV1). FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Change in doubling concentration was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure, and 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>log2 mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Day 56 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.062" spread="1.1309"/>
                    <measurement group_id="O2" value="-1.423" spread="0.4059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 84 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.1410"/>
                    <measurement group_id="O2" value="-1.846" spread="0.0431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Early termination (n=3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.514" spread="0.8636"/>
                    <measurement group_id="O2" value="0.417" spread="0.9840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FEV1 was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0: Predose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.718" spread="0.5458"/>
                    <measurement group_id="O2" value="2.640" spread="0.3994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 30 minutes postdose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.684" spread="0.5695"/>
                    <measurement group_id="O2" value="2.624" spread="0.4126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 6 hours postdose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.606" spread="0.5731"/>
                    <measurement group_id="O2" value="2.550" spread="0.4304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.814" spread="0.6048"/>
                    <measurement group_id="O2" value="2.606" spread="0.2919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.323" spread="0.5703"/>
                    <measurement group_id="O2" value="2.520" spread="0.0812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Predose (n=5, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.598" spread="0.4676"/>
                    <measurement group_id="O2" value="2.850" spread="0.2082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 30 minutes postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.535" spread="0.5639"/>
                    <measurement group_id="O2" value="2.918" spread="0.2822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 6 hours postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.400" spread="0.5254"/>
                    <measurement group_id="O2" value="2.665" spread="0.2748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 (n= 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.260" spread="0.5464"/>
                    <measurement group_id="O2" value="2.778" spread="0.4228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: Predose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.555" spread="0.6718"/>
                    <measurement group_id="O2" value="2.700" spread="0.3677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 30 minutes postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.705" spread="0.7990"/>
                    <measurement group_id="O2" value="2.830" spread="0.1697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 6 hours postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.510" spread="0.7071"/>
                    <measurement group_id="O2" value="2.690" spread="0.2404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (n= 2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.505" spread="0.6859"/>
                    <measurement group_id="O2" value="2.580" spread="0.0283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.680" spread="0.7778"/>
                    <measurement group_id="O2" value="2.540" spread="0.4101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination (n=4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.018" spread="0.5803"/>
                    <measurement group_id="O2" value="2.867" spread="0.4400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>The FVC was volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, 63, 84 or early termination (any time before Day 84)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>The FVC was volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0: Predose (n= 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.828" spread="0.8215"/>
                    <measurement group_id="O2" value="3.666" spread="0.6068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 30 minutes postdose (n= 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.823" spread="0.6500"/>
                    <measurement group_id="O2" value="3.722" spread="0.6752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 6 hours postdose (n= 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.808" spread="0.7718"/>
                    <measurement group_id="O2" value="3.722" spread="0.7297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n= 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.988" spread="0.6058"/>
                    <measurement group_id="O2" value="3.824" spread="0.7415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.462" spread="0.5926"/>
                    <measurement group_id="O2" value="3.710" spread="0.5220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Predose (n=5, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.908" spread="0.7670"/>
                    <measurement group_id="O2" value="3.883" spread="0.6412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 30 minutes postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.878" spread="0.7876"/>
                    <measurement group_id="O2" value="3.980" spread="0.7951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 6 hours postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.810" spread="0.7409"/>
                    <measurement group_id="O2" value="3.790" spread="0.4830"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.613" spread="0.6874"/>
                    <measurement group_id="O2" value="3.920" spread="0.7777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: Predose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.700" spread="0.5233"/>
                    <measurement group_id="O2" value="3.410" spread="0.3818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 30 minutes postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.775" spread="0.5303"/>
                    <measurement group_id="O2" value="3.540" spread="0.4667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 6 hours postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.715" spread="0.6435"/>
                    <measurement group_id="O2" value="3.545" spread="0.3748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.705" spread="0.5162"/>
                    <measurement group_id="O2" value="3.575" spread="0.5020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84: (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.710" spread="0.6505"/>
                    <measurement group_id="O2" value="3.415" spread="0.3323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination (n=4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.908" spread="0.8070"/>
                    <measurement group_id="O2" value="4.193" spread="0.8364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) as Percentage of Forced Vital Capacity (FVC)</title>
        <description>Percentage of FEV1 was calculated as (FEV1/FVC)*100. It signified the percentage of the total amount of air exhaled from the lungs during the first second of forced exhalation. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Predose, 30 minutes and 6 hours post-end of infusion on Day 0, 28 and 56; Day 4, 14, 35, Day 63, 84 or early termination (any time before Day 84)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) as Percentage of Forced Vital Capacity (FVC)</title>
          <description>Percentage of FEV1 was calculated as (FEV1/FVC)*100. It signified the percentage of the total amount of air exhaled from the lungs during the first second of forced exhalation. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>percentage of FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0: Predose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.875" spread="10.3156"/>
                    <measurement group_id="O2" value="72.600" spread="11.4149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 30 minutes postdose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.250" spread="9.1613"/>
                    <measurement group_id="O2" value="71.600" spread="13.1833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0: 6 hours postdose (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.125" spread="12.5178"/>
                    <measurement group_id="O2" value="69.600" spread="12.1984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4 (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.000" spread="13.1909"/>
                    <measurement group_id="O2" value="69.400" spread="8.7063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 (n=6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.667" spread="7.5011"/>
                    <measurement group_id="O2" value="68.800" spread="8.1670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: Predose (n=5, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.400" spread="13.1263"/>
                    <measurement group_id="O2" value="74.500" spread="11.2694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 30 minutes postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.500" spread="13.9881"/>
                    <measurement group_id="O2" value="74.500" spread="9.6782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28: 6 hours postdose (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.750" spread="12.3390"/>
                    <measurement group_id="O2" value="71.250" spread="13.8173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35 (n=4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.500" spread="7.5498"/>
                    <measurement group_id="O2" value="71.750" spread="7.8049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: Predose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.000" spread="8.4853"/>
                    <measurement group_id="O2" value="80.000" spread="19.7990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 30 minutes postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.000" spread="11.3137"/>
                    <measurement group_id="O2" value="81.000" spread="15.5563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56: 6 hours postdose (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.000" spread="7.0711"/>
                    <measurement group_id="O2" value="76.500" spread="14.8492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.500" spread="9.1924"/>
                    <measurement group_id="O2" value="72.500" spread="9.1924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.500" spread="9.1924"/>
                    <measurement group_id="O2" value="75.500" spread="19.0919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination (n=4, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.750" spread="9.8107"/>
                    <measurement group_id="O2" value="69.000" spread="5.5678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire (ACQ) Total Score</title>
        <description>The ACQ is questionnaire that comprises of 7-questions evaluating participant’s asthma control. Six self-administered questions assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; using 7-point ordinal rating scale from 0 (good control) to 6 (poor control). Seventh question is completed by a health professional on forced expiratory volume in 1 second (FEV1) percentage (%) predicted; scale: 0 (greater than [&gt;] 95% predicted) to 6 (less than [&lt;] 50% predicted. Final score is the average score of the 7 questions, with a score range of 0 (well controlled) to 6 (extremely poor controlled). Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
        <time_frame>Baseline, Day 28, 56, 84 or early termination (any time before Day 84)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire (ACQ) Total Score</title>
          <description>The ACQ is questionnaire that comprises of 7-questions evaluating participant’s asthma control. Six self-administered questions assess asthma control over the past week covering nocturnal waking, morning symptoms, activity limitations, shortness of breath, wheezing, and short-acting bronchodilator use; using 7-point ordinal rating scale from 0 (good control) to 6 (poor control). Seventh question is completed by a health professional on forced expiratory volume in 1 second (FEV1) percentage (%) predicted; scale: 0 (greater than [&gt;] 95% predicted) to 6 (less than [&lt;] 50% predicted. Final score is the average score of the 7 questions, with a score range of 0 (well controlled) to 6 (extremely poor controlled). Result was summarized for sub-therapeutic dose (placebo and CAT-354 1 mg/kg) and therapeutic dose (CAT-354 5 mg/kg and CAT-354 10 mg/kg), as per planned analysis.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication. Here, 'n' signifies those participants who were evaluable for this measure at specified time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.737"/>
                    <measurement group_id="O2" value="1.77" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=5, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.416"/>
                    <measurement group_id="O2" value="1.46" spread="0.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="0.808"/>
                    <measurement group_id="O2" value="1.50" spread="1.111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=2, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="1.010"/>
                    <measurement group_id="O2" value="2.36" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Termination (n=5, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.304"/>
                    <measurement group_id="O2" value="0.57" spread="0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.</description>
        <time_frame>Day 0 to 84</time_frame>
        <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The FEV1 was maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration.</description>
          <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Diary Data</title>
        <description>Participants recorded asthma symptoms, use of reliever inhalers (beta-agonist use for symptom relief and as prophylaxis), and morning and evening peak expiratory flow (PEF) measurements in a diary.</description>
        <time_frame>Day 0, 4, 14, 28, 35, 56, 63 to Day and 84</time_frame>
        <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Diary Data</title>
          <description>Participants recorded asthma symptoms, use of reliever inhalers (beta-agonist use for symptom relief and as prophylaxis), and morning and evening peak expiratory flow (PEF) measurements in a diary.</description>
          <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Exacerbations</title>
        <description>Exacerbation was defined as: Mild (determined from diary data) - 2 consecutive days satisfying the same or 1 of the following criteria: any night with awakening(s) due to asthma or morning PEF 20 % or more below baseline where baseline = average of the 10 days before randomization or as-needed medication use of 2 inhalations or more in 24 hours above baseline where baseline = average of the 10 days before randomization. Severe (determined by taking an exacerbation update and history): deterioration of asthma resulting in emergency treatment or hospitalization or need for oral steroids for 3 days or more (as judged by the Investigator).</description>
        <time_frame>Day 0 to Day 84</time_frame>
        <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Exacerbations</title>
          <description>Exacerbation was defined as: Mild (determined from diary data) - 2 consecutive days satisfying the same or 1 of the following criteria: any night with awakening(s) due to asthma or morning PEF 20 % or more below baseline where baseline = average of the 10 days before randomization or as-needed medication use of 2 inhalations or more in 24 hours above baseline where baseline = average of the 10 days before randomization. Severe (determined by taking an exacerbation update and history): deterioration of asthma resulting in emergency treatment or hospitalization or need for oral steroids for 3 days or more (as judged by the Investigator).</description>
          <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Flow and Peak Flow Variability</title>
        <description>Peak flow is a participant’s maximum speed of expiration.</description>
        <time_frame>Day 0 to Day 84</time_frame>
        <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Flow and Peak Flow Variability</title>
          <description>Peak flow is a participant’s maximum speed of expiration.</description>
          <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adult Asthma Quality of Life (QoL) Questionnaire Final Score</title>
        <description>The AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants are asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. The 4 domain scores are the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).</description>
        <time_frame>Day 0, 28, 84 or early termination (any time before Day 84)</time_frame>
        <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Therapeutic-dose (CAT-354 5mg/kg and CAT-354 10mg/kg)</title>
            <description>CAT-354 5 mg/kg or 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>Sub-therapeutic Dose (Placebo or CAT-354 1mg/kg)</title>
            <description>Placebo or CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Adult Asthma Quality of Life (QoL) Questionnaire Final Score</title>
          <description>The AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants are asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions. The 4 domain scores are the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment).</description>
          <population>Data was not collected and hence, not analyzed for this outcome measure because the study was prematurely terminated on the basis of several factors namely, observed low rate of participant randomisation into the study; delay caused by temporary halt of study and potential for expiry date of investigation medicinal product before end of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Serum Concentration (Cmax) for CAT-354</title>
        <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
        <population>Pharmacokinetic (PK) population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Serum Concentration (Cmax) for CAT-354</title>
          <population>Pharmacokinetic (PK) population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>microgram/milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="219">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="163">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After second dose (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="255">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="235">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After third dose (Day 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="338">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="251">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Observed Serum Concentration (Cmin) for CAT-354</title>
        <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
        <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Observed Serum Concentration (Cmin) for CAT-354</title>
          <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="51.8">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="52.8">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After second dose (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.91">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="54.1">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="64.4">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After third dose (Day 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.70">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="85.5">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="68.4">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC [0 - t]) for CAT-354</title>
        <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
        <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration Time Curve From Time Zero to Last Measurable Concentration (AUC [0 - t]) for CAT-354</title>
          <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>microgram*day/milliliter (mcg*day/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After first dose (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="2820">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="2090">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After second dose (Day 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="4720">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="3080">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After third dose (Day 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="3690">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="3420">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Accumulation Ratio for CAT-354 (RA)</title>
        <description>Accumulation ratio (RA) is calculated for Cmax, Cmin and AUC as RA for Cmax = Cmax (56 - 84)/Cmax (0 - 28); Similarily, RA for Cmin = Cmin (56 - 84)/Cmin (0 - 28) and RA for AUC= AUC (56 - 84)/AUC (0 - 28) where Cmax (0 - 28) and Cmax (56 - 84) are the maximum observed serum concentration after first dose (Day 0 to Day 28) and after third dose (Day 56 to Day 84), respectively; Cmin (0 - 28) and Cmin (56 - 84) are the minimum observed serum concentration after first and third dose, respectively; AUC (0 - 28) and AUC (56 - 84) are the area under the serum concentration time curve over a dosage interval determined after first and third dose, respectively.</description>
        <time_frame>Predose, 10 minutes and 6 hours post-end of infusion on Day 0, 28 and 56</time_frame>
        <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio for CAT-354 (RA)</title>
          <description>Accumulation ratio (RA) is calculated for Cmax, Cmin and AUC as RA for Cmax = Cmax (56 - 84)/Cmax (0 - 28); Similarily, RA for Cmin = Cmin (56 - 84)/Cmin (0 - 28) and RA for AUC= AUC (56 - 84)/AUC (0 - 28) where Cmax (0 - 28) and Cmax (56 - 84) are the maximum observed serum concentration after first dose (Day 0 to Day 28) and after third dose (Day 56 to Day 84), respectively; Cmin (0 - 28) and Cmin (56 - 84) are the minimum observed serum concentration after first and third dose, respectively; AUC (0 - 28) and AUC (56 - 84) are the area under the serum concentration time curve over a dosage interval determined after first and third dose, respectively.</description>
          <population>PK population included all participants who received at least 1 dose of study medication and had sufficient post-dose blood samples to estimate Cmax. Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RA for Cmin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="1.54">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="1.73">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA for Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="1.65">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="1.30">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA for AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O2" value="1.31">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                    <measurement group_id="O3" value="1.64">Standard deviation was not estimable because only 1 participant was evaluable in this reporting group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 84 that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Day 0 to 84</time_frame>
        <population>Safety population included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O2">
            <title>CAT-354 1 mg/kg</title>
            <description>CAT-354 1 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O3">
            <title>CAT-354 5 mg/kg</title>
            <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
          <group group_id="O4">
            <title>CAT-354 10 mg/kg</title>
            <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Day 84 that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety population included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to 84</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56</description>
        </group>
        <group group_id="E2">
          <title>CAT-354 1 mg/kg</title>
          <description>CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="E3">
          <title>CAT-354 5 mg/kg</title>
          <description>CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
        <group group_id="E4">
          <title>CAT-354 10 mg/kg</title>
          <description>CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA. 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA. 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The Principal Investigator (PIs) also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was prematurely terminated due to low recruitment rate, delay due to temporary halt and potential for expiry date of study drug. It was not considered possible to draw meaningful conclusions from the small dataset.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Meena Jain, MB BChir/Associate Medical Director</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-0000</phone>
      <email>jainm@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

